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Abstract Xanthine oxidase (XO) is an enzyme responsible
for the production of uric acid. XO produces considerable
amount of oxidative stress throughout the body. To date,
however, its pathophysiologic role in hypertension and endo-
thelial dysfunction still remains controversial. To explore the
possible involvement of XO-derived oxidative stress in the
pathophysiology of vascular dysfunction, by use of a selective
XO inhibitor, febuxostat, we investigated the impact of phar-
macological inhibition of XO on hypertension and vascular
endothelial dysfunction in spontaneously hypertensive rats
(SHRs). Sixteen-week-old SHR and normotensive Wistar-
Kyoto (WKY) rats were treated with tap water (control) or
water containing febuxostat (3 mg/kg/day) for 6 weeks.
Systolic blood pressure (SBP) in febuxostat-treated SHR
(220±3 mmHg) was significantly (P<0.05) decreased com-
pared with the control SHR (236±4 mmHg) while SBP in
febuxostat-treated WKY was constant. Acetylcholine-
induced endothelium-dependent relaxation in aortas from
febuxostat-treated SHR was significantly (P<0.05) improved
compared with the control SHR, whereas relaxation in re-
sponse to sodium nitroprusside was not changed. Vascular XO
activity and tissue nitrotyrosine level, a representative indica-
tor of local oxidative stress, were considerably elevated in the
control SHR compared with the control WKY, and this incre-
ment was abolished by febuxostat. Our results suggest that
exaggerated XO activity and resultant increase in oxidative
stress in this experimental model contribute to the hyperten-
sion and endothelial dysfunction, thereby supporting a notion
that pharmacological inhibition of XO is valuable not only for
hyperuricemia but also for treating hypertension and related
endothelial dysfunction in human clinics.
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Xanthine oxidoreductase (XOR) catalyzes the oxidation of
hypoxanthine to xanthine and on to uric acid, which are the
final reactions of purine catabolism in humans. Under phys-
iological conditions, the enzyme functions mainly as a dehy-
drogenase (XDH) and uses NAD+ as the electron acceptor.
Noticeably, under a variety of pathologic conditions such as
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tissue ischemia and tissue damage (Harrison 2002), it can be
converted into an oxidase (xanthine oxidase (XO)) using mo-
lecular oxygen as the electron acceptor.
Because of its ability to generate reactive oxygen species
(ROS), the role of XOR has long been investigated in a wide
variety of ROS-related diseases (Boueiz et al. 2008).
Hypertension is a major risk for cardiovascular diseases. A
large body of evidence suggests that locally exaggerated ox-
idative stress is profoundly involved in the pathophysiology of
hypertension (Nickenig and Harrison 2002; Ceriello 2008;
Cutler et al. 2008; Grossman 2008). In accordance with this
notion, augmented oxidative stress has been implicated in
vascular dysfunction of several models of experimental hyper-
tension ((Fukui et al. 1997; Kerr et al. 1999; Tanito et al. 2004;
Touyz 2004). In particular, endothelial dysfunction is a hall-
mark of hypertension (Lockette et al. 1986; Morawietz et al.
2001; Landmesser et al. 2003), which is also evoked by ox-
idative stress. As one of underlying mechanisms, it is sug-
gested that oxidative stress reduces bioavailability and bioac-
tivity of nitric oxide (NO), a potent endothelium-derived
relaxing factor (Li et al. 2013).
Based on the notion that XO produces ROS, it is reasonable
to speculate that XO would ameliorate hypertension and as-
sociated endothelial dysfunction. However, conflicting re-
sults have been reported depending on the experimental hy-
pertensive models (Tian et al. 2005; Zhang et al. 2005;
Yamamoto et al. 2006; Ong et al. 2007; Viel et al. 2008). It
also should be noted that most of previous studies used al-
lopurinol to attain the pharmacological XO inhibition.
Importantly, allopurinol is a classic suicide inhibitor, as its
binding to and reduction of the Mo cofactor induce self-
oxidation to form oxypurinol, an active inhibitory metabolite.
Reduction of the Mo cofactor by allopurinol leads to ROS
production (Galbusera et al. 2006). On the other hand, allopu-
rinol is known to exert radical scavenging effect due to its
chemical structure (Augustin et al. 1994). For these reasons,
it seems to be hard to precisely evaluate the pharmacological
effect of XO inhibition by allopurinol. In contrast, febuxostat
is a novel, selective, and potent XO inhibitor with non-purine
structure for treating gout in human clinics. Unlike allopuri-
nol, febuxostat does not produce or scavenge ROS by its
chemical structure, because it is neither a suicide XO inhibitor
nor a radical scavenger (Okamoto et al. 2003). In this sense,
febuxostat would be better tool to resolve the issue whether
pharmacological XO inhibition reduces blood pressure and
improves the endothelial dysfunction in experimental models.
To explore the possible involvement of XO-derived ox-
idative stress in the pathophysiology of vascular dys-
function, we evaluated the impact of febuxostat on hyper-
tension and vascular endothelial dysfunction in spontane-
ously hypertensive rats (SHRs), representative animal
model of human essential or primary hypertension
(Zicha and Kunes 1999).
Materials and methods
Animals and treatments
Male SHRs and age-matched Wistar-Kyoto (WKY) rats
weighing 200–300 g were purchased from Charles River
Japan (Yokohama, Japan) and were maintained under stan-
dard conditions until the experiments were done. All studies
were performed in accordance with procedures approved by
the Animal Ethics Committee of the Teijin Institute for Bio-
Medical Research Institute, Teijin Pharma Limited, Tokyo,
Japan.
Four groups of rats were used in this study: (1) WKY
control rats (WKY-C), (2) febuxostat-treated WKY rats
(WKY-Fx), (3) control SHR (SHR-C), and (4) febuxostat-
treated SHR (SHR-Fx). WKY-C and SHR-C groups were
given tap water. TheWKY-Fx and SHR-Fx groups were given
febuxostat dissolved in drinking water ad libitum at a concen-
tration of 0.03 mg/L. At this concentration, the dose of
febuxostat per day calculated by the daily water intake and
body weight was approximately 3 mg/kg/day. As a matter of
fact, we recently found that single oral administration of
febuxostat at 1, 3, and 10 mg/kg to rats showed dose-
dependent inhibition of XO activity in plasma and aorta (data
not shown). It should be noted that repeated administration of
XO inhibitor at high dose in rodents results in death, partly
because xanthine calculi caused renal impairment due to inhi-
bition of XOD/XDH (Isa et al. 1968). According to this no-
tion, oral administration of febuxostat at 10 mg/kg for 28 days
caused calculi in 1 of 30 animals (Horiuchi et al. 1999). In this
context, to achieve the maximal inhibition of XO and avoid
possible renal damages, we carefully selected 3 mg/kg/day as
a dose of febuxostat. The febuxostat treatment was started at
16 weeks of age and carried out for 6 weeks. Systolic blood
pressures (SBPs) were measured before and 2, 4, and 6 weeks
during the drug treatment. Vascular function, XO activity, and
other biochemical parameters were determined at 6 weeks.
Blood pressure measurement
SBP was measured using a tail-cuff sphygmomanometer
(Visitech BP2000, Visitech Systems, Apex, NC). All animals
were acclimated for blood pressure measurements 1 week
before drug treatment.
Xanthine oxidase activity
Plasma and tissue XO activities were measured by the pterin-
based assay. In brief, frozen tissues were homogenized with
potassium phosphate buffer, pH 7.4, containing 1 mM ethyl-
enediaminetetraacetic acid (EDTA) and protease inhibitors.
The homogenates were centrifuged 12,000 rpm for 15 min
at 4 °C, and supernatants were co-incubated with 50-μM
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pterin solution to assay XO activity. After 60-min incubation
at 37 °C, fluorometric assays were performed to calculate the
production of isoxanthopterin. Activity of purified XO de-
rived from buttermilk (Calbiochem) and protein concentration
were measured and used to normalize the sample activity.
In vitro organ bath studies
The animals were sacrificed at the end of the 6-week study by
decapitation under pentobarbital anesthesia. The thoracic aor-
ta was isolated carefully and cut into 3-mm-length ring. The
ring segments were mounted in organ baths containing 5 mL
of Krebs-Henseleit solution aerated with 95 % O2 and 5 %
CO2 and warmed at 37 °C. The composition of Krebs-
Henseleit solution is as follows (mM): NaCl (119), KCl
(4.7), CaCl2 (2.5), MgSO4 (1.2), NaHCO3 (25), KH2PO4
(1.2), and glucose (10); pH7.4. Each ring was connected to
a force transducer (FD, NIHON KODEN, Tokyo, Japan) for
isometric force recording. The rings were stretched to 2 g of
optimal tension and equilibrated for 60 min until a stable
baseline tone was obtained.
Following equilibration, the rings were repeatedly exposed
to 60 mM KCl, and then, the presence of endothelium was
verified by the ability of acetylcholine (ACh, 1×10−6 M) to
relax phenylephrine (PE, 1 ×10−7 M)-induced contraction.
After washout, endothelium-mediated relaxation was mea-
sured as a concentration-response curve to ACh (1×10−10–
1×10−4 M) in rings contracted with the submaximal dose of
PE (5×10−7 M). Endothelium-independent relaxation was
also measured as a concentration-response curve to sodium
nitroprusside (SNP) (1×10−10–1×10−4 M).
Oxidative stress measurement
Tissues were weighed and homogenized with 0.05 M potas-
sium phosphate buffer, pH 7.4, containing 1 mM EDTA and
protease inhibitors. Homogenates were centrifuged at 12,
000 rpm for 15 min at 4 °C, and the supernatants were col-
lected and used for assay. The measurement of nitrotyrosine
was performed by using a commercially available
nitrotyrosine assay kit (Northwest Life Science, CA, USA)
according to the manufacturer’s instructions.
Plasma uric acid level
Plasma uric acid levels were determined by an enzymatic
method based on the ur icase-peroxidase sys tem
(PUREAUTO® S CRE-N, Sekisui Medical Co. Ltd., Japan).
Statistical analysis
Data are expressed asmean±SEM. The responses to ACh and
SNP are expressed as percentages of PE contraction.
Statistical calculations for significant differences were per-
formed by using Student’s t test. Significance was accepted at
P<0.05.
Results
General conditions of animals
Febuxostat treatment did not alter the body weight in both
WKY rats and SHRs. The plasma uric acid levels were similar
inWKY-C and SHR-C groups (Table 1). Febuxostat treatment
significantly decreased plasma uric acid levels in both WKY
rats and SHRs to the same extent (0.9±0.1 mg/dL inWKY-C,
0.5±0.1 mg/dL in WKY-Fx, 1.0±0.1 mg/dL in SHR-C, and
0.5±0.1 mg/dL in SHR-Fx; Table 1).
Systolic blood pressure
SBP in the SHR-C group was significantly higher compared
to that in the WKY-C group. Febuxostat treatment significant-
ly (P<0.05) decreased SBP in the SHRs (236±4 mmHg in
SHR-C, 220±3 mmHg in SHR-Fx, Fig. 1), while it did not
alter SBP in the WKY rats after 6-week treatment (164
±7 mmHg in WKY-C, 156±9 mmHg in WKY-Fx, Fig. 1).
Vascular and plasma xanthine oxidase activity
XO activity in the thoracic aorta of SHRs was significantly
higher than that of WKY rats (Fig. 2a). The treatment with
febuxostat lowered this activity in both strains (957±214 μU/
mg protein inWKY-C, 463±114 μU/mg protein in WKY-Fx,
2549±427 μU/mg protein in SHR-C, and 805±73 μU/mg
protein in SHR-Fx, Fig. 2a). Similarly, the level of XO activity
in plasma of SHRs was significantly higher than that of WKY
rats (Fig. 2b). Treatment with febuxostat reduced this activity
in both strains (80.5±2.2 mU/mL in WKY-C, 19.0±2.5 mU/
mL in WKY-Fx, 113.4 ±6.4 mU/mL in SHR-C, and 31.7
±2.1 mU/mL in SHR-Fx, Fig. 2b).
Vascular oxidative stress
To investigate the therapeutic effect of febuxostat on oxidative
stress, we examined the tissue nitrotyrosine level.
Nitrotyrosine, a marker of nitro-oxidative stress in the thoracic
aorta of SHRs, was significantly higher than that of WKY rats
(Fig. 3). The treatment with febuxostat lowered nitrotyrosine
concentration in both strains (Fig. 3).
Vascular reactivity
Finally, we evaluated the effect of febuxostat on endothelial
function. ACh-induced endothelium-dependent relaxation in
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the thoracic aorta was attenuated in SHR compared to that of
WKY rats (P<0.01, Fig. 4a). Febuxostat treatment restored
the endothelium-dependent relaxation in comparison to the
untreated SHRs (P < 0.05, Fig. 4a). The endothelium-
independent relaxation measured using SNP, a direct NO do-
nor, was similar in SHRs and WKY rats (Fig. 4b). Febuxostat
treatment did not alter the relaxation in response to SNP in
both WKY rats and SHRs.
Discussion
By using a novel, selective xanthine oxidase inhibitor
febuxostat, the present study aimed to investigate the ther-
apeutic effects of pharmacological inhibition of XO on hyper-
tension and endothelial dysfunction in SHRs. Our data dem-
onstrated that the therapeutic dose of febuxostat appropriate
for hyperuricemia considerably decreased the SBP, reduced
the vascular and plasma XO activity, suppressed the vascular
nitrotyrosine level, and improved endothelial dysfunction in
SHR.
Improvement in hypertension and endothelial dysfunction
Our results showed that the therapeutic dose of
febuxostat appropriate for hyperuricemia significantly
ameliorated hypertension in SHR. On the other hand, a
couple of studies showed that chronic treatment with
allopurinol, a classic type of XO inhibitor, failed to
lower blood pressure in SHRs (Trachtman et al. 1991;
Laakso et al. 1998, 2004; Yamamoto et al. 2006). With
respect to the possible mechanisms for the inconsistent
results between the two XO inhibitors, a couple of pos-
sibilities are raised as follows. First, allopurinol does
produce oxidative stress when metabolized to oxypurinol
as described above (Galbusera et al. 2006), while
febuxostat does not. Second, both allopurinol and
oxypurinol showed the limitation to inhibit the
endothelial-binding xanthine oxidase (Kelley et al.
2004; Malik et al. 2011). Third, allopurinol has been
shown to be more nephrotoxic in SHR than in WKY,
thereby masking its beneficial effect on hypertension
(Trachtman et al. 1991). These may explain, at least in
part, the difference in impact on hypertension of SHR
between allopurinol and febuxostat.
XO inhibitors such as tungsten and allopurinol have been
reported to improve endothelial dysfunction in several animal
models and human diseases such as atherosclerosis and cor-
onary heart disease (Schroder et al. 2006; Dopp et al. 2011;
George et al. 2006; Yiginer et al. 2008). Our recent work
demonstrated that febuxostat improved endothelial dysfunc-
tion also in high-fat diet-induced obese diabetic mice
(Masuzaki et al., manuscript submitted). Based on our results
in various experimental hypertension models, XO inhibitors
may exert favorable effects in several types of endothelial
dysfunction.
Mechanism of action of XO inhibition
In the present study, XO activities in both aorta and plasma
from SHRs were significantly elevated as compared to that
of WKY rats. Importantly, treatment of febuxostat substan-
tially lowered aorta and plasma XO activities in both
strains. Circulating XO binds to glycosaminoglycan resi-
dues on the surface of endothelium in a partially heparin-
reversible manner and subsequently translocates to intra-
cellular compartments (Radi et al. 1997; Houston et al.
1999). Although mechanisms whereby plasma XO activity
is elevated in SHRs are not yet entirely clarified, it has
been reported that XO is released from several organs into
systemic circulation in a line of pathophysiology including
hepatitis, hemorrhagic shock, sickle cell disease, and is-
chemia reperfusion (Yokoyama et al. 1990; Tan et al. 1998;
Aslan et al. 2001). SHRs represent a variety of organ dam-
ages related to severe hypertension (Liu et al. 2011; Boon
Table 1 Body weight and plasma uric acid
WKY-C WKY-Fx SHR-C SHR-Fx
BW (g) 376 ± 5 370 ± 6 384 ± 4 387 ± 4
Uric acid (mg/dL) 0.9 ± 0.1 0.5 ± 0.1** 1.0 ± 0.1NS 0.5 ± 0.1##
Values are means ± SEM (n= 9∼10 per group)
NS not significant WKY-C vs SHR-C, Student’s t test






























Fig. 1 Systolic blood pressure (SBP) in untreated and febuxostat-treated
(3 mg/kg/day) spontaneously hypertensive rats andWKY rats. Values are
means ± SEM (n = 4∼5 per group). *P < 0.05, **P < 0.01 SHR-C vs
SHR-Fx, NS not significant WKY-C vs WKY-Fx, Student’s t test
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et al. 2013). Therefore, XO derived from damaged organs
may contribute to the elevation of plasma and vascular XO
activities in SHRs.
Our data demonstrated that endothelial relaxation by
ACh was improved in febuxostat-treated SHRs compared
with the vehicle-treated SHRs, while the response to SNP in
aorta was unaltered. Enhanced ACh-induced relaxation in
vascular endothelium by febuxostat is attributed, at least
partly, to the increase in NO response, resulting from the
scavenge of NO by ROS, which reacts rapidly with NO to
form peroxynitrite (Trujillo et al. 1998). To assess the in-
volvement of NO scavenge in this experimental paradigm,
we measured vascular nitrotyrosine levels. Protein
nitrosylation is a representative indicator of peroxynitrite
formation in vascular tissues. As expected, SHRs showed
significantly elevated nitrotyrosine levels in the aortic ho-
mogenate as compared to WKY rats, which were norma-
lized by the treatment of febuxostat. Thus, the data suggest
that febuxostat attenuates NO scavenge and subsequently
increases the availability of NO. Furthermore, peroxynitrite
per se induces endothelial and tissue injuries in various
pathophysiological conditions (Pacher et al. 2002a, b,
2005; Szabo et al. 2002a, b, 2004; Ungvari et al. 2005).
Hence, suppression of peroxynitrite by febuxostat is also
beneficial to ameliorate endothelial dysfunction.
It is well documented that elevation of serum uric acid
per se is a potent risk for dysfunction of kidney and vas-
cular system, resulting in hypertension (Sundstrom et al.
2005; Galbusera et al. 2006; Krishnan et al. 2007; Grayson
et al. 2011). In animal models, hyperuricemia in rats leads
to increase in blood pressure, while the alleviation of hy-
peruricemia with urate-lowering drugs including
benzbromarone leads to the reversal of hypertension
(Mazzali et al. 2001; Nakagawa et al. 2003; Sanchez-
Lozada et al. 2008a, b). In clinical settings, reduction of
uric acid with allopurinol in hyperuricemic, hypertensive
adolescents did ameliorate blood pressure profile (Feig et
al. 2008). In contrast to these findings, the present study
used SHRs and the control normotensive WKY rats and
compared the results to minimize the possible influence
of uric acid-dependent actions, because the serum uric acid
level in SHRs is similar to WKY rats (Trachtman et al.
1991; Durante et al. 2010). Treatment of febuxostat
equipotently lowers plasma uric acid levels in both WKY
rats and SHRs and ameliorated hypertension in SHRs, sug-
gesting that the BP-lowering effects of febuxostat are
caused by the suppression of ROS production independent
of the lowering effect on plasma uric acid. Comparison
study using XO inhibitors and other hypouricemic agents
such as benzbromarone would be required to test this
hypothesis.
Study limitations
In the present study, the dose of febuxostat was limited to
about 3 mg/kg/day, because the higher dose of febuxostat
highly causes xanthine calculi as described (Isa et al.
1968). As a matter of fact, febuxostat at 3 mg/kg/day could
not attain the complete inhibition of XO systemically in
this study. Therefore, we could not assess the maximal
Fig. 2 Xanthine oxidase activity
in aorta (a) and plasma (b)
obtained from spontaneously
hypertensive rats and WKY rats.
Values are means ± SEM (n= 6
per group). tP< 0.05, ttP< 0.01
WKY-C vs WKY-Fx, **P< 0.01
WKY-C vs SHR-C, ##P< 0.01
SHR-C vs SHR-Fx, Student’s t
test
t
Fig. 3 Effect of febuxostat on vascular nitrotyrosine levels in untreated
and febuxostat-treated (3 mg/kg/day) spontaneously hypertensive rats
and WKY rats. Values are means ± SEM (n = 6 per group). tP < 0.05
WKY-C vs WKY-Fx, **P< 0.01 WKY-C vs SHR-C, ##P< 0.01 SHR-
C vs SHR-Fx, Student’s t test
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effects of febuxostat on the hypertension and endothelial
dysfunction in the current experimental setting. The pres-
ent study used SHR as a representative animal model of
hypertension and demonstrated the potential anti-
hypertensive effects by pharmacological XO inhibition.
Recently, Boban et al. reported that circulating xanthine
oxidase activity was increased in patients with essential
hypertension (Boban et al. 2014), which is consistent with
our results that plasma XO activity was considerably ele-
vated in SHR. Therefore, XO inhibitor may be beneficial
for the treatment of some forms of hypertension in humans.
However, there is little information about the relationship
between plasma XO activity and other forms of hyperten-
sion such as renal hypertension and pulmonary hyperten-
sion. In this context, further studies are warranted to clarify
the clinical implication of XO inhibition in various types of
diseases.
With respect to the prediction of clinical efficacy of XO
inhibition, we should be careful about extrapolating the results
in experimental animals to humans. Importantly, unlike
humans, almost all animals including rodents have uricase, a
urate oxidase enzyme. Although few animal species that mim-
ic uric acid metabolism in humans are known (Oda et al. 2002;
Bannasch et al. 2008), there seems no available model of
hypertension in these species. Therefore, clinical studies are
required to verify the effects of XO inhibition on the
hypertension and endothelial dysfunction in human
pathophysiology.
In conclusion, present study demonstrates that exaggerated
XO activity and resultant increase in oxidative stress in SHRs
contribute, at least partly, to their hypertension and endothelial
dysfunction. This notion was endorsed by the finding that
chronic treatment of selective XO inhibitor febuxostat
improves a line of vascular phenotypes. Our data suggest that
pharmacological inhibition of exaggerated XO may be
valuable not only for hyperuricemia but also for treating some
forms of hypertension and related endothelial dysfunction in
humans.
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